Takeda Pharmaceutical Company Limited (TAK)
USD 13.11
(-1.87%)
USD 13.11
(-1.87%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 7834.78 Billion JPY | 3.05% |
| 2023 | 7603.07 Billion JPY | 1.45% |
| 2022 | 7494.49 Billion JPY | -3.11% |
| 2021 | 7735.11 Billion JPY | -4.43% |
| 2020 | 8093.6 Billion JPY | -7.06% |
| 2019 | 8708.73 Billion JPY | 316.87% |
| 2018 | 2089.05 Billion JPY | -13.2% |
| 2017 | 2406.81 Billion JPY | 32.76% |
| 2016 | 1812.88 Billion JPY | -13.26% |
| 2015 | 2090.01 Billion JPY | 3.03% |
| 2014 | 2028.5 Billion JPY | 17.1% |
| 2013 | 1732.24 Billion JPY | 15.09% |
| 2012 | 1505.16 Billion JPY | 131.65% |
| 2011 | 649.74 Billion JPY | -1.33% |
| 2010 | 658.52 Billion JPY | -6.77% |
| 2009 | 706.34 Billion JPY | 34.1% |
| 2008 | 526.74 Billion JPY | -13.84% |
| 2007 | 611.38 Billion JPY | -11.89% |
| 2006 | 693.86 Billion JPY | 27.54% |
| 2005 | 544.02 Billion JPY | -1.92% |
| 2004 | 554.65 Billion JPY | 12.82% |
| 2003 | 491.63 Billion JPY | -2.82% |
| 2002 | 505.88 Billion JPY | 1.65% |
| 2001 | 497.69 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 7834.78 Billion JPY | 3.05% |
| 2024 Q4 | 7834.78 Billion JPY | 4.74% |
| 2024 Q3 | 7480.34 Billion JPY | -4.11% |
| 2024 Q1 | 7871.06 Billion JPY | 7.58% |
| 2024 Q2 | 7800.86 Billion JPY | -9.22% |
| 2023 Q3 | 7328.2 Billion JPY | -6.95% |
| 2023 Q2 | 7875.35 Billion JPY | 1.64% |
| 2023 FY | 7603.07 Billion JPY | 1.45% |
| 2023 Q1 | 7748.04 Billion JPY | 3.38% |
| 2023 Q4 | 7603.07 Billion JPY | 3.75% |
| 2022 Q3 | 7366.69 Billion JPY | 1.81% |
| 2022 Q1 | 7418.59 Billion JPY | -4.09% |
| 2022 Q2 | 7235.91 Billion JPY | -2.46% |
| 2022 FY | 7494.49 Billion JPY | -3.11% |
| 2022 Q4 | 7494.49 Billion JPY | 1.73% |
| 2021 Q1 | 7923.08 Billion JPY | -2.11% |
| 2021 FY | 7735.11 Billion JPY | -4.43% |
| 2021 Q2 | 7748.24 Billion JPY | -2.21% |
| 2021 Q4 | 7735.11 Billion JPY | 1.16% |
| 2021 Q3 | 7646.7 Billion JPY | -1.31% |
| 2020 Q2 | 8010.45 Billion JPY | -7.67% |
| 2020 Q1 | 8675.97 Billion JPY | -0.38% |
| 2020 Q3 | 8155.27 Billion JPY | 1.81% |
| 2020 Q4 | 8093.6 Billion JPY | -0.76% |
| 2020 FY | 8093.6 Billion JPY | -7.06% |
| 2019 Q4 | 8708.73 Billion JPY | 133.81% |
| 2019 Q2 | 2102.67 Billion JPY | 0.46% |
| 2019 Q1 | 2093 Billion JPY | 0.19% |
| 2019 FY | 8708.73 Billion JPY | 316.87% |
| 2019 Q3 | 3724.64 Billion JPY | 77.14% |
| 2018 Q4 | 2089.05 Billion JPY | -8.23% |
| 2018 FY | 2089.05 Billion JPY | -13.2% |
| 2018 Q3 | 2276.47 Billion JPY | 0.27% |
| 2018 Q2 | 2270.25 Billion JPY | -1.68% |
| 2018 Q1 | 2309.13 Billion JPY | -4.06% |
| 2017 Q4 | 2406.81 Billion JPY | 14.74% |
| 2017 Q3 | 2097.62 Billion JPY | 9.09% |
| 2017 Q1 | 1947.72 Billion JPY | 7.44% |
| 2017 Q2 | 1922.77 Billion JPY | -1.28% |
| 2017 FY | 2406.81 Billion JPY | 32.76% |
| 2016 Q2 | 2031.51 Billion JPY | -2.76% |
| 2016 Q4 | 1812.88 Billion JPY | -10.59% |
| 2016 FY | 1812.88 Billion JPY | -13.26% |
| 2016 Q3 | 2027.5 Billion JPY | -0.2% |
| 2016 Q1 | 2089.22 Billion JPY | -0.04% |
| 2015 Q3 | 2080.5 Billion JPY | 1.94% |
| 2015 Q1 | 1983.33 Billion JPY | -2.23% |
| 2015 Q4 | 2090.01 Billion JPY | 0.46% |
| 2015 Q2 | 2040.87 Billion JPY | 2.9% |
| 2015 FY | 2090.01 Billion JPY | 3.03% |
| 2014 Q4 | 2028.5 Billion JPY | 2.84% |
| 2014 FY | 2028.5 Billion JPY | 17.1% |
| 2014 Q3 | 1972.54 Billion JPY | 3.49% |
| 2014 Q2 | 1906.04 Billion JPY | 15.02% |
| 2014 Q1 | 1657.19 Billion JPY | -4.33% |
| 2013 Q4 | 1732.24 Billion JPY | 4.27% |
| 2013 FY | 1732.24 Billion JPY | 15.09% |
| 2013 Q1 | 1517.75 Billion JPY | 0.84% |
| 2013 Q2 | 1510.96 Billion JPY | -0.45% |
| 2013 Q3 | 1661.31 Billion JPY | 9.95% |
| 2012 Q3 | 1446.5 Billion JPY | -0.53% |
| 2012 Q4 | 1505.16 Billion JPY | 4.06% |
| 2012 FY | 1505.16 Billion JPY | 131.65% |
| 2012 Q1 | 597.15 Billion JPY | -8.09% |
| 2012 Q2 | 1454.23 Billion JPY | 143.52% |
| 2011 Q2 | 595.18 Billion JPY | -0.7% |
| 2011 Q3 | 587.53 Billion JPY | -1.29% |
| 2011 Q4 | 649.74 Billion JPY | 10.59% |
| 2011 FY | 649.74 Billion JPY | -1.33% |
| 2011 Q1 | 599.37 Billion JPY | -8.98% |
| 2010 Q4 | 658.52 Billion JPY | 1.85% |
| 2010 Q3 | 646.57 Billion JPY | -0.7% |
| 2010 Q2 | 651.11 Billion JPY | 0.0% |
| 2010 FY | 658.52 Billion JPY | -6.77% |
| 2009 FY | 706.34 Billion JPY | 34.1% |
| 2009 Q4 | 706.34 Billion JPY | 11.09% |
| 2009 Q3 | 635.81 Billion JPY | 0.0% |
| 2008 FY | 526.74 Billion JPY | -13.84% |
| 2007 FY | 611.38 Billion JPY | -11.89% |
| 2006 FY | 693.86 Billion JPY | 27.54% |
| 2005 FY | 544.02 Billion JPY | -1.92% |
| 2004 FY | 554.65 Billion JPY | 12.82% |
| 2003 FY | 491.63 Billion JPY | -2.82% |
| 2002 FY | 505.88 Billion JPY | 1.65% |
| 2001 FY | 497.69 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 3.45 Billion USD | -226827.049% |
| Bausch Health Companies Inc. | 27.43 Billion USD | -28460.761% |
| Catalent, Inc. | 6.14 Billion USD | -127315.645% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -660728.947% |
| Elanco Animal Health Incorporated | 8.13 Billion USD | -96162.293% |
| Perrigo Company plc | 6.04 Billion USD | -129589.267% |
| Teva Pharmaceutical Industries Limited | 35.35 Billion USD | -22061.593% |
| Zoetis Inc. | 9.29 Billion USD | -84190.35% |